Deciphering Diseases and Biological Targets for Environmental Chemicals using Toxicogenomics Networks by Audouze, Karine Marie Laure et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 17, 2017
Deciphering Diseases and Biological Targets for Environmental Chemicals using
Toxicogenomics Networks
Audouze, Karine Marie Laure; Juncker, Agnieszka; Roque, francisco jose sousa simôes almeida;
Krysiak-Baltyn, Konrad; Weinhold, Nils; Taboureau, Olivier ; Jensen, Thomas Skøt; Brunak, Søren
Published in:
P L o S Computational Biology (Online)
Link to article, DOI:
10.1371/journal.pcbi.1000788
Publication date:
2010
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Audouze, K. M. L., Juncker, A., Roque, F. J. S. S. A., Krysiak-Baltyn, K., Weinhold, N., Taboureau, O., ...
Brunak, S. (2010). Deciphering Diseases and Biological Targets for Environmental Chemicals using
Toxicogenomics Networks. P L o S Computational Biology (Online), 6(5), e1000788. DOI:
10.1371/journal.pcbi.1000788
Deciphering Diseases and Biological Targets for
Environmental Chemicals using Toxicogenomics
Networks
Karine Audouze, Agnieszka Sierakowska Juncker, Francisco J. S. S. A. Roque, Konrad Krysiak-Baltyn, Nils
Weinhold, Olivier Taboureau, Thomas Skøt Jensen, Søren Brunak*
Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark
Abstract
Exposure to environmental chemicals and drugs may have a negative effect on human health. A better understanding of
the molecular mechanism of such compounds is needed to determine the risk. We present a high confidence human
protein-protein association network built upon the integration of chemical toxicology and systems biology. This
computational systems chemical biology model reveals uncharacterized connections between compounds and diseases,
thus predicting which compounds may be risk factors for human health. Additionally, the network can be used to identify
unexpected potential associations between chemicals and proteins. Examples are shown for chemicals associated with
breast cancer, lung cancer and necrosis, and potential protein targets for di-ethylhexyl-phthalate, 2,3,7,8-tetrachlorodiben-
zo-p-dioxin, pirinixic acid and permethrine. The chemical-protein associations are supported through recent published
studies, which illustrate the power of our approach that integrates toxicogenomics data with other data types.
Citation: Audouze K, Juncker AS, Roque FJSSA, Krysiak-Baltyn K, Weinhold N, et al. (2010) Deciphering Diseases and Biological Targets for Environmental
Chemicals using Toxicogenomics Networks. PLoS Comput Biol 6(5): e1000788. doi:10.1371/journal.pcbi.1000788
Editor: Olaf G. Wiest, University of Notre Dame, United States of America
Received September 11, 2009; Accepted April 15, 2010; Published May 20, 2010
Copyright:  2010 Audouze et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work has been supported by BioSim (NoE), FP6, LSHB-CT-2004-005137, the Villum Kann Rasmussen Foundation and the Innovative Medicines
Initiative Joint Undertaking (IMI-JU) for the eTOX project (115002). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: brunak@cbs.dtu.dk
Introduction
Humans are daily exposed to diverse hazardous chemicals via
skincare products, plastic cups, computers and pesticides to
mention but a few sources. The potential effect of these
environmental compounds on human health is a major concern
[1–2]. For example chemicals such as phthalate plasticizers have
been widely linked to allergies, reproductive disorders and
neurological defects. Humans are intentionally exposed to drugs
used for treatment and cure of diseases. Many drugs affect multiple
targets and may interact or affect the same proteins as
environmental chemicals [3–5]. The mechanism of action of
these small molecules is often not completely understood and can
be associated to adverse and toxic effects through for example
drug-drug interactions [6]. There is thus a need to improve our
understanding of the underlying mechanism of action of chemicals
and the biological pathways they perturb to fully evaluate the
impact of small molecules on human health.
An essential step towards deciphering the effect of chemicals on
human health is to identify all possible molecular targets of a given
chemical. Various network-oriented chemical pharmacology
approaches have been published recently to identify novel protein
candidates for drugs, using structural chemical similarity [7–10].
For example Keiser et al. [8] applied network analysis to drugs and
their targets. The authors identified unexpected molecular targets
such as muscarinic acetylcholine receptor M3, alpha-2 adrenergic
receptor and neurokinin NK2 receptor for methadone, emetine
and loperamide, respectively. Additionally, recent studies have
demonstrated that chemicals could be classified based upon their
effect on mRNA expression detected by microarrays [11–12].
Lamb et al. showed that genomic signatures could be used to
recognize drugs with common mechanism of action allowing
discovery of unknown modes of action. Despite the explosion of
chemical-biological networks, the chemical toxicity remains a
major issue in human health. Analysis of environmental chemicals
with similar gene expression profiles is still lacking. With the recent
advances in toxicogenomics, information on gene/protein activity
in response to small molecule exposures becomes more available.
This provide necessary data to develop computational systems
biology models to predict both high level associations (linking
chemical exposures to diseases) and more detailed associations
(linking chemicals to proteins)
In this paper we present a method that can associate chemicals
to disease and identify potential molecular targets based on the
integration of toxicogenomics data, chemical structures, protein-
protein interaction data, disease information and functional
annotation. The core of our procedure is derived from the ‘‘target
hopping’’ concept defined previously [3]. But instead of consid-
ering only binding activity, we extended the concept to gene
expression. If two proteins are affected with two chemicals, then
both proteins are deemed associating in chemical space. Our
approach is not only a statistical model but mimics the true
biological system by constructing a network of associations
between human proteins defined as Protein-Protein Association
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Network (P-PAN). We have validated our network by comparison
with two high confidence protein-protein interaction (PPI)
networks, and by assessing the functional enrichment of clusters
in the network generated. The P-PAN revealed both known as
well as many novel surprising connections between chemicals and
diseases or proteins. We provide literature support for some of the
unexpected associations, such as the connection between diethyl-
hexylphthalate (DEHP) and gamma-aminobutyric acid A receptor
beta target [13], as well as between apocarotenal, a chemical
found in spinach, and necrosis. This illustrates the usefulness of an
approach that integrates toxicogenomics data with other diverse
data types.
Results
Based on the Comparative Toxicogenomics Database (CTD)
[14], we constructed a human P-PAN. A workflow of the strategy
is shown on Figure 1. We extracted 42,194 associations between
2,490 chemicals and 6,060 human proteins from the CTD. We
mapped compounds to chemical structures from PubChem and
extracted their indication of use from Medical Subject Headings
(MeSH, http://www.nlm.nih.gov/mesh/MBrowser.html) to clas-
sify them as either drugs (MeSH: ‘‘Pharmaceutical Actions’’) or
environmental chemicals (MeSH: ‘‘Toxic Actions’’ and ‘‘Specialty
Uses of Chemicals’’).
In the CTD, drugs and environmental compounds are claimed
to be associated with toxicologically important proteins. To
estimate how much the information from the CTD differs from
available data on pharmacological action of drugs, we compared
the data shared between CTD and DrugBank, as of May 2009
[15]. DrugBank is a repository of pharmacological action for
‘Food and Drug Administration’ approved drugs. From the 1358
drugs gathered in DrugBank, 420 drugs matched in CTD.
Interestingly, whereas 1403 proteins are associated to these drugs
in DrugBank, only 194 proteins are found in both databases. For
example, according to Drug Bank celecoxib, a known non-
steroidal anti-inflammatory drug, is associated to two metabolizing
enzymes: the Cytochrome P450 2C9 (CYP2C9) and the
Cytochrome P450 2D6 (CYP2D6) and to two drug targets: the
Prostaglandin G/H synthase 2 (COX-2) and the 3-phosphoino-
sitide-dependent protein kinase 1 (PDPK1). In the CTD, celecoxib
is linked to 33 human proteins including CYP2C9 and COX-2.
The toxicity information extracted from CTD is relatively
different to the known pharmacological action of drugs and
should be considered as a complementary source of information.
Structure-target relationship
To investigate the assumption that two compounds sharing similar
structure can potentially affect the same molecular targets, we
compared chemical properties of the compounds collected from the
CTD. The chemicals were characterized by 50 properties calculated
from the structure, including the molecular mass and affinity for a
lipid environment. The distribution of properties, as it appears in a
multi-dimensional properties space, was projected and visualized in
two dimensions using principal component analysis (PCA) (shown in
Figure 1). There is substantial overlap in the PCA projections
between environmental chemicals and drugs indicating that they can
potentially affect the same protein targets. We also compared the oral
bioavailability profiles of compounds based on standard Lipinski [16]
and Veber [17] rules. Again, overlaps were observed, indicating that
environmental chemicals mimic drug properties (see Figure S1).
These results confirm that it is reasonable to generate a network by
integrating toxicogenomics knowledge from both drugs and
environmental compounds, as they share many properties.
Generating a high confidence human Protein-Protein
Association Network
The human P-PAN was generated based on the assumption that
if two proteins are biologically affected with the same chemicals
(defined as shared chemicals), they are likely to be involved in a
common mechanism of action of the chemicals. Then, two
proteins are connected to each other if they are linked to the same
chemical in the CTD. The resulting P-PAN consists of 2.44
million associations. To reduce noise and select the most
significant associations, we assigned two reliability scores to each
protein-protein association: a score based on hypergeometric
calculation and a weighted score. The weighted score was
calculated as the sum of weights for shared chemicals, where
weights were inversely proportional to the number of associated
proteins for a given compound.
We went one-step further and compared the P-PAN with two
human PPI databases: (1) a high confidence set of experimental
PPIs extracted from a compilation of diverse data sources [18] and
(2) PPIs based on an internal consistent single data source [19].
Our P-PAN performed well compared to both PPIs. Based on the
calibration curves (Figure S2), we considered a threshold that
capture good overlaps between our P-PAN and the PPI networks
for different reliability scores thus reducing our P-PAN to
,200,000 reliable associations. Using this approach, the molec-
ular target predictions are limited to the 3,528 proteins present in
the P-PAN. To confirm that biological information is not lost
when selecting only 8% of the entire P-PAN, we compared
functional enrichment for the complete network (6,060 proteins)
and for the high confidence sub-network (3,528 proteins) using
Gene Ontology (GO) [20]. For example cell proliferation (p-values
of 3.22e-36 and 1.46e-27 for the large network and the sub-
network, respectively) and protein binding (p-values of 1.2e-72 and
4.13e-47 for the large network and the sub-network, respectively)
were the most overrepresented terms.
Since proteins tend to function in groups, or complexes, an
important step has been to verify that our high confidence network
mimics true biological organization. This task is commonly
Author Summary
Exposure to environmental chemicals and drugs may have
a negative effect on human health. An essential step
towards understanding the effect of chemicals on human
health is to identify all possible molecular targets of a
given chemical. Recently, various network-oriented chem-
ical pharmacology approaches have been published.
However, these methods limit the protein prediction to
already known molecular drug targets. New findings can
for example be made by using high-confidence protein-
protein association databases. Here, we describe a generic,
computational systems biology model with the aim of
understanding the underlying molecular mechanisms of
chemicals and the biological pathways they perturb. We
present a novel and complementary approach to existing
models by integrating toxicogenomics data, chemical
structures, protein-protein interaction data, disease infor-
mation and functional annotation of proteins. The high
confidence protein-protein association network proposed
reveals unexpected connections between chemicals and
diseases or human proteins. We provide literature support
to demonstrate the validity of some predictions, and
thereby illustrate the power of an approach that integrates
toxicogenomics data with other data types.
PPA Network using Toxicogenomics Data
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executed using graph clustering procedures, which aim at
detecting densely connected regions within the interaction graph.
Two clustering methods have been applied to our network. The
molecular complex detection (MCODE) approach [21] that allows
multiple clusters assignation for a protein, mimicking the reality as
a protein can participate in several complexes simultaneously. On
the other hand, the markov cluster algorithm (MCL) [22] which
assign one protein to a unique cluster has been shown to be
superior to other graph clustering methods in recent studies [23–
24]. Applied on our network, MCODE extracted few large core
clusters and several tiny clusters (possibly singleton clusters). The
MCODE approach results in a clustering arrangement with a
weak cluster-wise separation. Compared to MCL, MCODE
yielded a lower number of clusters, with a higher number of
proteins per cluster. Only 35 clusters varying in size from five to
845 proteins were extracted. Using the MCL algorithm we
obtained a more heterogeneous separation with 58 clusters varying
in size from five to 462 proteins. Therefore, to identify the
Figure 1. Workflow of the strategy for generating a human P-PAN and predicting novel associations. DATA: Extraction and filtering of
human protein-chemical associations from CTD. The visualization of the chemical space by Principal Component Analysis projection confirms that
drugs (D) and environmental chemicals (E) shared structural properties, and then may affect similar protein targets. The two first principal
components, which explained about 44% of the variance on the calculated properties are shown (green: pharmaceutical actions, red: toxic actions
and blue: specialty uses of chemical). All proteins (P) were mapped to Ensembl gene identifiers to facilitate further data integration. MODEL
GENERATION: Construction of the P-PAN. The P-PAN was created from associations present in the CTD (dashed edge lines) between chemicals and
proteins. In the P-PAN, two proteins are connected to each other (edge lines) if they share a common chemical. A weighted score, represented by the
width of the black edges, was assigned to each protein-protein association. It represents the strength of the network between two proteins as
defined by the number of shared compounds for both molecular targets. Selection of a scoring function and a high confidence P-PAN after overlaps
comparison with two human interactomes (PPIs) based on experimental evidences. Clustering of the P-PAN and evaluation of the biological
meaningful of the clusters using Gene Ontology annotations. PREDICTION: (1) Prediction of novel molecular targets for chemical using a neighbor
protein procedure. DEHP (orange) is known to be connected with blue proteins and is predicted to be associated with green proteins. A confidence
score was calculated for each protein, represented by the width of the edges; thick edge for high score to thin edge for low score. (2) Prediction of
disease associated with chemical after integration of protein-disease information using GeneCards in clusters. As example, apocarotenal, a compound
found in spinach is predicted to be link to necrosis.
doi:10.1371/journal.pcbi.1000788.g001
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biologically meaningfulness of our network, we used complexes
extracted using the MCL method. Each cluster was then
investigated for functional enrichment based on GO terms. To
ensure the high quality of functional annotations we used only
annotations experimentally supported or with traceable references.
Hypergeometric testing was used to determine GO functional
annotation overrepresented amongst each cluster. The two top
scoring molecular functions found were heme binding (p-value of
6.60e-25, cluster 4) and glucuronosyl transferase activity (p-value
of 2.34e-21, cluster 12). Regulation of apoptosis (p-value of
1.67e.17, cluster 2) and oxidation reduction (p-value of 6.67e-14,
cluster 4) were the most highly enriched categories in the biological
process branch of the GO. This analysis thus confirms that clusters
in the network, and therefore the proteins associated with each
other, are functionally coherent. This was further evidence that the
organization of the network is meaningful.
Diseases associated to clusters
In the clusters of the P-PAN, proteins are more connected with
other proteins within the cluster than with the other targets in the
network. As proteins are associated based on their shared
relationship with chemicals, proteins within a given cluster tend to
be more linked to specific compounds. It is thus possible to find
associations between diseases and the chemicals that underlie the
protein-protein associations within the cluster using protein-specific
disease annotations. For each cluster, we investigated if specific
disease annotation was found more frequently than expected by
using protein-disease information [25]. We identified several
diseases associated with specific clusters. These included the two
most common types of cancer, breast cancer (cluster 1, p-value of
9.67e-18) and lung cancer (cluster 12, p-value of 4.84e-12), as well as
necrosis (cluster 2, p-value of 2.26e-12), ichthyosis (a skin disorder
associated to cluster 4, p-value of 1.41e-5), retinoblastoma (cluster 7,
p-value of 9.46e-8) and inflammation (cluster 8, p-value of 1.55e-5).
Mining the network for chemicals associated with
disease
To predict which chemicals may affect human health, we then
analyzed selected clusters to identify new chemical-disease
associations (see Table 1). When linking diseases to compounds,
it is important to keep in mind that there is no direction in the
association, i.e. it is not possible from the network to separate
positive from negative associations between a chemical and a
disease. Discriminating between whether a compound prevents or
causes disease requires manual interpretation of the association.
One of the clusters showed high enrichment for breast cancer.
The most significantly associated chemicals are already known
from the literature to be related to cancer, thus supporting the
clustering quality of the P-PAN. Among the most significantly
associated chemicals are the well-known polychlorinated biphenyls
(PCBs). PCBs are used for a variety of applications i.e. flame
retardants, paints and plasticizers. After being banned due to their
toxicity, they still persist in the environment. Previous results
suggest that specific PCBs may indeed be associated with breast
cancer [26]. Several organizations (EPA, IARC) have classified
PCBs as probable human carcinogens. When we inspected
another cluster highly connected to lung cancer using our P-
PAN method, thimerosal, dinitrochlorobenzene (DNCB) and
styrene were significantly associated with this cluster. Thimerosal
and DNCB are not known lung cancer-causing chemicals, while
the last compound, styrene has been classified as a possible
carcinogen. Thimerosal is an organomercury chemical widely
used as preservative in health care products and in vaccines. It
may have possible adverse health effects such as a role in autism
and in nervous system disorders [27] as well as possible gene-toxic
effects to human lymphocytes [28]. No study has previously
related it to lung cancer. The second chemical DNCB is known to
be a skin allergen that may cause dermatitis. Genes associated with
allergies were shown to be up regulated in rat lung tissue after
DNCB exposure [29], but no direct link to lung cancer has been
demonstrated so far. Another interesting finding is the association
between apocarotenal and necrosis. Apocarotenal, a natural
carotenoid found in spinach and citrus, is used as a red-orange
coloring agent (E160E) in foods, pharmaceuticals and cosmetics
products. No direct evidence has been found that links
apocarotenal to necrosis. However, in vitro and in vivo studies
[30] have suggested that spinach may be a good anti-cancer agent.
This is in line with epidemiologic studies that have shown that
those who consume higher dietary levels of fruits and vegetables
have a lower risk of certain types of cancer [31] due to the
presence of carotenoids. Furthermore, carotenoids have been
defined as chemopreventive agents [32]. Studies have established
associations between carotene and beta-carotene with reduced risk
of prostate cancer [33] or breast cancer [34]. The prediction that
apocarotenal is positively associated to necrosis and could prevent
certain types of cancer is thus indirectly supported by other studies.
The other chemicals significantly associated to disease (Table 1)
are discussed in the supplementary text (see Text S1).
Predicting novel molecular targets for chemicals
Besides revealing disease-chemical associations, the network can
be used to predict novel targets for chemicals. It has been shown
that many small molecules affect multiple proteins rather than a
single target, and that proteins sharing an interaction with a
Table 1. Mining the P-PAN for chemicals associated with
breast cancer, lung cancer and necrosis, using a clustering
procedure.
Cluster ID Disease Chemical name p-Value
1
(462 proteins)
Breast cancer
(128 proteins)
estradiol 7.68e-134
bisphenol A 4.46e-92
PCBs 1,15e-88
genistein 2.20e-78
fulvestrant 7.05e-63
12
(59 proteins)
Lung cancer
(29 proteins)
thimerosal 1.57e-26
(10 proteins)
DNCB 3.29e-22
(12 proteins)
styrene 7.78e-06
2
(433 proteins)
Necrosis
(122 proteins)
arsenic disulfide 4.76e-35
apocarotenal 1.63e-29
(8 proteins)
doxorubicin 2.66e-26
Chemicals already known from the literature to be associated to disease are
shown in italic. In bold are the chemicals significantly associated to disease,
which are unknown to be disease-causing chemical from the literature. The
number of proteins is shown in brackets for each cluster, disease and novel
association. As example, among the 433 proteins associated to cluster 2, 122
are known to be linked to necrosis. Among these 122, 8 are connected to
apocarotenal in CTD.
doi:10.1371/journal.pcbi.1000788.t001
PPA Network using Toxicogenomics Data
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chemical are targeted by the same chemicals [8]. Based on the
CTD data available, strong promiscuities between some proteins
exist. For example, more of 25% of chemicals annotated to
estrogen receptor 1 (ESR1) affects also progesterone receptor
(PGR). In the same order, cytochrome p450 2D6 (CYP2D6) and
cytochrome p450 2C9 (CYP2C9) shared one-third of their
respective associated compounds. By the term ‘‘affected’’, we
consider effects such as up regulated, down regulated, agonist,
antagonist and inhibitor. Then, our network can not be used to
identify chemical synergies or opposite effect on proteins. Thus, if
two proteins are affected by two chemicals and one of the proteins
is further deregulated by an additional chemical, then it might be
that both proteins are in fact deregulated with the same three
chemicals. Based on this assumption and in order to suggest novel
associations between chemicals and proteins, a neighbor protein
procedure was used which scored the association between each
protein and each chemical (see Materials and Methods). Molecular
targets known to be associated with a chemical were extracted
from the CTD, and the P-PAN was scanned for proteins
associated with a high score. The significance of enrichment was
calculated by random testing (for the confidence scores see Text
S2), and sub-networks were subsequently ordered according to
their significance. Four examples of various chemicals are
presented in Table 2 (other case stories are shown in Table S1).
To estimate the performance of our approach for approved drugs,
we analyzed the level of recall and precision obtained for the 420
common drugs between DrugBank and CTD. We obtained a
recall and a precision of 5.91% and 3.77% respectively,
corresponding to the percentage of interactions in DrugBank
retrieved and percentage of interactions in DrugBank from all
interactions predicted obtained from CTD data and from the
neighbor protein procedure. These values illustrate that informa-
tion between the two data sources are relatively different.
Examples of proteins associated to chemicals
Phthalates, mainly used as plasticizers, have received a lot of
attention as environmental compounds because they are potential
human carcinogens. As there are many phthalates, we focused on
Di-EthylHexyl Phthalate (DEHP) that has been associated with
more proteins compared to other phthalates such as additional
information on kinases (e.g. mitogen-activated protein kinase 1, and
mitogen-activated protein kinase 3) [35]. DEHP is widely used due
to its suitable properties and low cost, and is present in the general
environment at high levels. Exposure to DEHP is of particular
concern with regard to developing fetuses where it is believed to
cause malformation of reproductive organs and neurological defects
[36]. Using our approach, several proteins were identified as being
associated with DEHP (Table 2). Cysteine dioxygenase type I
(CD01) and peroxisome proliferator-activated receptor alpha
(PPARA), the two top scoring proteins, are already known in the
CTD and from the literature [37–38] as molecular targets for
DEHP. Six other high ranking proteins are new potential DEHP
molecular targets which are not recorded in the CTD (thus not input
data). Among them, four gamma-aminobutyric acid A (GABA)
receptors were predicted as potential DEHP molecular targets.
These associations are supported by a recent study showing that
DEHP can modulate the function of ion channels as GABA
receptors in a manner similar to volatile anesthetics in experiments
on expressed receptors [13]. This makes sense because the GABA
neurotransmitter system has been implicated in the pathogenesis of
bipolar disorders (neurological disorders) via gamma-aminobutyric
acid receptor subunit alpha-1 (GABAa1) [39], and DEHP is also
associated with neurological defects [36]. In addition to GABA
receptors, we identified several other candidates including proopio-
melanocortin (POMC) and a cytochrome P450 (CYP3A11)
(discussed in the Text S2). We looked at another environmental
chemical, the 2,3,7,8-TetraChloroDibenzo-p-Dioxin (TCDD),
which originates from burning or incineration of chlorinated
industrial compounds. TCDD is believed to cause a wide variety
of pathological alterations, with the most severe being progressive
anorexia and body weight loss [40]. TCDD is also known to be a
neurotoxin leading to neurodevelopmental and neurobehavioral
deficits [41–42], and accumulating in the brain as well as other
organs [43]. We identified six proteins associated with TCDD that
are not recorded in the CTD for human (Table 2). Among them five
are supported by literature (see Text S2). This included protein
kinase C elipson (PRKCE), known to be involved in brain tumors
Table 2. Predicting novel molecular targets for chemicals.
Chemical
Known
protein Cpscore*
Novel
protein Cpscore*
Liter-
ature
DEHP CDO1 13.23 GABAß1 5.46 Yes
PPARA 9.48 POMC 5.44 Yes
SUOX 4.35 CYP3A11 5.40 Yes
(15 proteins) GABAß2 4.32 Yes
GABAc2 4.32 Yes
GABAa1 4.26 Yes
TCDD HSPA9B 82.69 PRKCE 10.17 Yes
SLC2A4 82.69 POMC 8.97 Yes
TRIP11 82.69 CPT1A 6.96 Yes
TSP1 82.69 HSD11B1 6.39 Yes
EPHX2 75.77 MVP 6.77 No
MT2A 10.85 APOB 5.61 Yes
(90 proteins)
PA CYP4X1 5.67 CHST1 5.19 No
PPARA 2.53 CHST4 5.19 No
CES1 1.45 CST 3.19 Yes
SULT2A1 0.87 ABCG5 2.61 No
CYP1A1 0.37 C3 2.80 Yes
ADRA2A 1.34 Yes
CYB5A 1.21 No
ADRA1A 1.08 Yes
CRHR2 1.04 No
CYP2A13 0.93 No
ALDH3 0.91 Yes
(5 proteins)
Permethrin AR 4.67 CYP2B1 4.43 Yes
WNT10B 4.12 SHBG 3.51 Yes
PGR 3.75 CYP2B6 2.89 No
ESR1 3.31 NR1I3 2.64 Yes
TFF1 3.15
NR1I2 2.94
(17 proteins)
*Proteins known to be associated to a compound were extracted from the CTD.
In brackets is the total number of known proteins used to query the P-PAN. To
find novel protein targets (in bold) associated to a chemical, a neighbor
proteins procedure was used which scored the association between proteins
and chemicals (cpscore). Among the novel predicted proteins (thus not input
data), some are supported by literature, highlighting the usefulness of the P-
PAN to identify new chemical-protein associations.
doi:10.1371/journal.pcbi.1000788.t002
PPA Network using Toxicogenomics Data
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[44], carnitine palmitoyltransferase I (CPT1A), 11b-hydroxysteroid
dehydrogenase type 1 (HSD11B1) and apolipoprotein B (APOB)
which are all linked to obesity [45–47]. Furthermore, we investigated
in detail the drug pirinixic acid (PA) (also named WY14,643), which
is a peroxisome proliferator-activated receptor (PPAR) agonist with
strong hypolipidemic effects. PA was never approved for clinical use
due to hepatocarcinogenesis adverse effect shown in animal studies
[48]. To date there is no evidence that PA promotes carcinogenesis
in humans [49], and this has spurred new studies for identifying
cellular processes that are capable of responding to PA. Among 11
molecular targets identified and not recorded in the CTD (Table 2),
only five are supported by the literature (see Text S2). For example
the expression of the C3 protein, an acylation stimulating protein
involved in necrosis and afibrinogenemia (blood disorders), has been
shown to be affected by PA in rats [50]. Finally we studied proteins
associated with permethrin in more detail. Permethrin is a widely
used insecticide, acaricide and insect repellent, classified by the US
EPA as a likely human carcinogen, but still used in healthcare for the
treatment of lice infestations and scabies. Four proteins not recorded
in the CTD were identified as associated with permethrin. Three of
them are supported by literature (see Text S2 for details) including a
cytochrome P450 (CYP2B1) [51–52] and sex hormone-binding
globulin (SHBG) [53], which are proteins linked to the endocrine
system. These findings suggest a mechanism by which chronic
exposure of humans to pesticides containing this compound may
result in disturbances in endocrine effects related to androgen action.
The examples we provide include both known and new protein
associations with a given chemical, and many of the novel
associations are supported by the literature. We compared our
approach with STRING (version STRING 1) [54] a high-
confidence protein-protein association network, to see if the
findings generated by the current approach are also found by
other existing methods. The STRING network includes direct
(physical) and indirect (functional) associations derived from
diverse sources as genomic context, high throughput experiments,
co-expression and literature. As a test example, we used the 15
proteins associated with DEHP in the CTD to query the P-PAN
by a neighbor protein procedure. The same 15 proteins were also
used to query the STRING network. Subsequently we compared
the predicted molecular targets between the two networks (P-PAN
and STRING). In the resulting STRING network none of the
GABA receptors were found (see Figure S3). The STRING
network showed a clear tendency to associate phthalates with
kinases and nuclear receptors. This example demonstrated that
our approach was complementary to other association approach-
es. This highlights the value of integrating various sources of data
to understand potential toxic effects on human health caused by
chemical exposure.
Discussion
We propose an approach different from existing computational
chemical biology networks, which primarily integrate drugs
information, to identify new molecular targets for chemicals and
to link them to diseases. In our approach we have integrated
toxicogenomics data for drugs and environmental compounds.
The ability to make new findings using a different network is
illustrated by a comparison with a similar method, showing the
capacity of our P-PAN to identify novel chemical-protein
associations. Using phthalate as an example, our model suggests
potential associations between DEHP and GABA receptors, which
have not been predicted previously.
An extension of this network by integrating more data, for
example other chemical-protein associations or dose levels for
which a compound may affect human health, would be beneficial
to the proposed approach. Paracelsus (1493–1541) is often cited
for his quote, ‘‘all things are poisons and nothing is without poison,
only the dose permits something not to be poisonous’’. This
emphasize that the dose of a chemical is an issue to consider in the
deregulation of systems biology. Nevertheless, a global mapping
could allow a better understanding of adverse effects of drugs and
toxic effects of environmental compounds. This could be used as a
new approach for risk assessment and regulatory decision-making
for human health.
Among the examples presented, some predictions are support-
ed by literature for other organisms. Regarding toxicogenomics,
the available human data are generally sparse compared to
rodents. Data on toxicity - adverse effects of chemicals on
humans – can be acquired through epidemiologic studies and
from occupational, accident-related exposures as intentional
human testing of environmental compounds remains limited.
However, differences exist between model animal and human
responses to chemicals, including differences in the type of
adverse effects experienced and the dosages at which they occur.
The differences may reflect variations in the underlying
biochemical mechanisms, in metabolism, or in the distribution
of the chemicals. As an example, bisphenol A (BPA) does not
affect proteins in a similar way across species (Figure 2). In the
human systems studied to date, BPA does not affect the proto-
oncogene c-FOS (FOS) and the mitogen-activated protein kinase
8 (MAKP8) but seems to modify their expression in rodent
species. BPA binds and modifies the activity of the estrogen
receptor alpha (ESR1) in a very conservative way across
organisms [14]. BPA has an ability to function as an estrogen
like receptor (ER) agonist, and thus has the potential to disrupt
normal endocrine signaling through regulation of ER target genes
e.g. androgen receptors, estrogen receptor, progesterone recep-
tors. There is a need to integrate data with cross-species
extrapolation in order to have a more accurate understanding
of the human risk from chemical exposure.
The major limitation of our integrative systems biology
approach is that the molecular target predictions are limited to
the 3,528 proteins present in our P-PAN, which represent only
15% of the estimated human proteome [55]. Hence, the current
lack of high quality data is the limiting factor in approaches such as
the one described here. Today high throughput methodologies
result in available large scale data in both chemical biology and
systems biology, but these data are discipline specific [56]. There is
an evident need for the development of databases [57] to integrate
disparate datasets such as toxicogenomics data in order progress in
systems biology research. In addition, the results of the disease-
compound association analysis will improve in the future as newer,
more complete and curated data will become available.
Materials and Methods
Data set
We downloaded the publicly available Comparative Toxicoge-
nomics Database (CTD) as of June 26, 2008 [14]. The CTD
contains curated information combining drug and environmental
chemical data associated with proteins. We selected 42,194
associations between 2,490 unique compounds and 6,060
molecular targets known to be involved in human disease.
Different associations are presented in the CTD such as ‘‘chemical
x results in increased expression of protein z’’ or ‘‘compound x
binds to protein z’’. Gene expression data are essentially present in
the CTD such as a chemical can increase, decrease or affect a gene
expression. However, only few binding data are present in CTD
PPA Network using Toxicogenomics Data
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and therefore integrated in our network: 3189 in total among the
42,194 associations. Scripts were used to remove associations with
negation such as ‘‘chemical x does not affect protein z’’.
Quality of chemical and protein annotations
To verify the uniqueness of chemicals, chemical names
extracted from the CTD were checked using PubChem (http://
Figure 2. Cross-species comparative toxicogenomics for bisphenol A (BPA). Molecular targets are represented as nodes, and colored by
gene family. Nodes presence represent available information extracted from the CTD and node absence are the unknown information. Colored nodes
defined that BPA affect the protein, while nodes are not colored when BPA does not affect the protein. This figure highlights similarities and
differences existing between animal model and human responses to chemical exposure.
doi:10.1371/journal.pcbi.1000788.g002
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pubchem.ncbi.nlm.nih.gov/) as of June 26, 2008 to avoid
synonymous names for the same compound. The few chemical
names not retrieved via the database were manually verified. To
determine overlaps with protein-protein interaction databases and
facilitate further data integration, the CTD protein names were
mapped to the corresponding Ensembl IDs [58] as of June 26,
2008. Only 1.5% of the 42,194 chemical-protein associations
could not be clearly identified.
Structure-target relationship
To investigate chemical space of drugs and environmental
compounds, 50 two-dimensional properties were calculated for
each structure extracted from PubChem. To visualize them,
principal component analysis (PCA) was performed. All necessary
data were calculated using the MOE software (Chemical
Computing Group version 2007.09)
Generating a high confidence human Protein-Protein
Associations Network
Relevant human chemical-protein associations collected from
the CTD were used to create a P-PAN. The maximum number of
molecular targets assigned to one compound ‘tert-Butylhydroper-
oxide’ was 1,189 and the maximum of chemicals assigned to one
protein, the cytochrome P450 3A4 (CYP3A4), was 276. The P-
PAN was generated by instantiating a node for each protein, and
linking by an edge any protein-protein pair where at least one
overlapping chemical was identified. Scripts were used to convert
the protein-protein associations into a non-redundant list of
associations. If proteins A and B are associated, the network may
have two associations, A–B and B-A. Only one of these
associations was retained in the P-PAN. We assigned two
reliability scores to each protein-protein association: a score based
on hypergeometric calculation and a weighted score. The
weighted score was calculated as the sum of weights for
overlapping compounds, where weights were inversely propor-
tional to the number of assigned proteins. The resulting P-PAN is
a complex structure containing a total of 2.44 million unique
associations between 6,060 human proteins.
Validating the protein-protein association score
The reliability of the weighted score was confirmed by fitting a
calibration curve of different scores against Lage’s PPIs18 (version
2.9) and Vidal’s PPIs19. Only 35,000 high confidence experimental
interactions were extracted from Lage’s PPI, which contains
interactions present in the largest databases (Reactome, KEGG…)
and data inferred from model organisms. Vidal’s PPIs are based
on an internal consistent single data source defined using yeast
two-hybrid system and contains 3111 interactions.The overlaps of
our P-PAN scores and Lage/Vidal PPIs are shown in Figure S2.
The benchmark revealed that the weighted score is superior to a
score calculated as the negative logarithm of p-values from a test in
hypergeometric distribution and a simple overlap count. To
estimate the robustness of the model, four thresholds selected from
the ‘weighted score’ curves (5%, 8%, 12.5% and 17%) of the
complete P-PAN were used to perform prediction for DEHP. At
5%, 73,000 associations between 2105 proteins were extracted.
The number of proteins is relatively stable at 8% and 12.5%.
However, the number of associations increased significantly from
200,080 to 306,000 including lower score associations in the
output file of prediction. The threshold of 17% corresponds to
415,000 associations between 3894 proteins. All thresholds showed
a good prediction with the GABA receptors for DEHP. As the
12% threshold already added some more noise in the prediction,
we decided to not include more proteins, in order to keep the most
significant associations. We then considered a threshold of 8%,
represented by the vertical line in Figure S2, which captured a
good overlap between our P-PAN and the PPI networks. This
selection represents 200,080 associations of the complete P-PAN.
Among the ,200,000 high confidence associations selected,
3,528 proteins were identified, and these were significantly
enriched among the high scoring protein-protein associations as
shown in Figure S2 (861 Lage’s PPI interactions corresponding to
24.4% were found among the top 5% of the high scoring protein-
protein associations). By comparison, only 1,852 of the high
confident interactions from Lage were identified in a random P-
PAN created by node permutation, and no enrichment was seen
for the random network. As example, the selection of high
confidence associations allowed to conserve only 803 proteins from
the 1189 proteins assigned to the ‘tert-Butylhydroperoxide’.
P-PAN clustering
A high confidence sub-network of ,200,000 protein-protein
associations was selected which contained 3,528 proteins. This
sub-network was highly interconnected, with the majority of
proteins belonging to a single large cluster. In order to increase the
resolution and facilitate biological interpretation, two clustering
methods were applied to the sub-network, MCODE [21] and
MCL [22]. We used the default settings for MCODE (fluff option
set to 0.1, mode score cutoff set to 0.2, degree cutoff set to 2), and
obtained 35 clusters. One major drawback of this algorithm is that
not all the proteins in the network were clustered. We used the
MCL algorithm with scheme and granularity parameters set to 7
for highest performance and granularity. With the MCL approach
we identified a total of 58 clusters as strongly interconnected, with
a minimum size of 5 proteins. These clusters were linked together
into a new network consisting of a scored cluster-cluster
association network. The association score between each cluster
pair was calculated from the mean of the P-PAN between each
pair of clusters. Each cluster was investigated for functional
analysis based on the three Gene Ontology categories (a)
molecular function, (b) biological processes, and (c) cellular
components as of January 2009. To reduce the noise and improve
the quality of the functional annotation, we only used the
functional annotation if it was experimentally supported or had
traceable references. The following GO evidence codes were
allowed: IMP (Inferred from Mutant Phenotype), IGI (Interfered
from Genetic Interaction), IPI (Inferred from Physical Interac-
tions) and IDA (Inferred from Direct Assay) and TAS (Traceable
Author Statement). At time of use the molecular function category
contained 5,981 proteins, the biological processes category 5,196
proteins, and the cellular components 5,151 proteins. We
compared human proteins present in GO categories with proteins
extracted from the CTD; 14.3% of the CTD proteins could not be
annotated for the molecular function, 16.6% for biological
processes and 14.9% for cellular components.
To identify chemicals associated with disease, protein-specific
information such as involvement in disease was integrated in each
cluster. The Online Mendelian Inheritance in Man database
(OMIM) [59] (July, 2009) and the GeneCards database [25]
(February, 2008) were considered as sources of protein-disease
connections. Various clusters were investigated. For example, cluster
1 contained 462 proteins. Using GeneCards, 269 proteins were
retrieved with disease annotations. Amongst these 269 proteins, 128
were associated to breast cancer (with give a p-value of 9.67e-18 for
breast cancer to cluster 1). Using OMIM, only 90 proteins among the
462 were retrieved with disease annotations. Looking at the cluster
enrichment with OMIM, we obtained at the top a non significant p-
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value of 0.0048 (corresponding to two proteins for paget disease of
bone). As another example, we analyzed the second cluster. Cluster 2
contained 433 proteins. 281 proteins were annotated to diseases in
Genecards, for only 78 proteins in OMIM. Additionally, cluster 2 has
a significant p-value of 2.26e-12 using GeneCards information for
necrosis. According to these results we decided to use GeneCards as a
source of protein-disease relationships. To avoid too many false
positive from Genecards, we set a significance cut-off value of the
GeneCards-AKS2 score based on a comparison with OMIM. This
was done by overlapping common protein-disease associations from
Genecards against OMIM (see Figure S4). The protein-disease
connections were kept with a minimum AKS2 score of 60 and p-
values were calculated for each disease present in clusters. Then,
chemical information from the CTD was integrated with each cluster
and p-values were assigned to each chemical. All p-values obtained
were calculated using hypergeometric testing, and were corrected for
multiple testing with Bonferroni correction [60]. The significance
cutoff for the corrected p-values was set to 0.05.
Neighbor protein procedure
To predict molecular targets for a chemical, a network-neighbor’s
pull down was done in a three steps procedure: (1) Selection of the
input protein(s): Extraction of the protein(s) known to be associated
with the selected chemical from the CTD. (2) Identification of
network(s) surrounding the input proteins by a neighbor proteins
procedure. In this procedure, our P-PAN was queried for the input
proteins, and associations between these were added. Next, the first
order interactors of all the input proteins were queried and added.
For each neighbor, a score was calculated taking into account the
topology of the surrounding network, based on the ratio between total
associations and associations with input proteins. Molecular targets
with a score higher than the threshold (0.1) were kept in the final sub-
network(s). This node inclusion parameter is in the conservative end
of the optimal range for protein-protein interaction networks18. As a
final step all proteins in the complex were checked for associations
among them and the missing one were added. (3) Establishment of a
confidence score for the surrounding network (cscore) and of a score
for each protein (cpscore): Each of the pulled down complexes was
tested for enrichment on our input set by comparing them against
1.0e4 random complexes for the protein-protein association set to
establish a cscore for each sub-network and a cpscore for each
connected proteins. The cpscore was used to rank proteins to select
potential molecular targets for chemicals. An illustration of cpscore is
available on Table S2 for approved drugs.
Postscript
All the CTD human protein-chemical associations were
extracted from the CTD on June 26, 2008. Subsequent updates
of CTD, as of June 25, 2009, did not change the overall trends or
conclusions of the present study.
Supporting Information
Figure S1 Structure-target relationship: Oral bioavailability
profiles.For drugs, permeability and absorption are properties
considered to be important for effective delivery systems, and they
receive special attention in pharmaceutical research. We chose to
focus on the oral bioavailability properties based on standard
Lipinski and Veber rules. It is important to keep in mind that the
rules serve as guidelines only - some classes of chemicals, like
antibiotics, do not respect the rules. The selected properties are the
molecular weight, the octanol/water partition coefficient (an
indication of the ability of a molecule to cross biological
membranes), the number of hydrogen bond-donor, the number
of hydrogen bond-acceptor and the number of rotatable bond.
The distributions of the different molecular properties have partial
overlaps indicating that small environmental molecules could
mimic drug properties. As an example, the distribution of the
molecular weight shows a similar profile for each of the three
MeSH categories, with a light tendency for ‘Toxic Actions’
chemicals to have a smaller molecular weight (MW). The mean of
MW for ‘Toxic Actions’ is 264 daltons whereas the mean of MW
for ‘Pharmaceutical Actions’ chemicals is 386 daltons.
Found at: doi:10.1371/journal.pcbi.1000788.s001 (0.06 MB
DOC)
Figure S2 Comparing overlaps between protein-protein associ-
ations and protein-protein interactions. To assess the reliability of
our protein-protein association scores, we fitted a calibration curve
of the different PPA scores against overlaps with two PPI
databases: the Vidal’s interactome and a highly confident set
from Lage et al. Vidal’s PPIs are based on an internal consistent
single data source defined using yeast two-hybrid system. Lage’s
PPIs contain interactions present in the largest databases and data
inferred from model organisms. All the interactions used from
Lage et al for the calibration curve are experimental (extracted
from Reactome, KEGG and experimental data from small scale
experiments). In both comparison, the weighted score (wscore, in
red) appears to be superior compared to the score derivates from a
hypergeometric test (hscore, in green) and to the random scores.
The vertical line represent the threshold selected, which
correspond to 8% of the complete P-PAN i.e. 200,080 proteins.
Found at: doi:10.1371/journal.pcbi.1000788.s002 (0.07 MB
DOC)
Figure S3 Molecular target predictions for DEHP: novelty of
the P-PAN. The novelty of our P-PAN is supported by comparing
the predicted proteins associated to DEHP using our approach
and an existing method String [1]. Blue nodes are the 15 input
proteins known to be associated to this chemical in CTD, green
nodes are the predicted proteins from String. Purple nodes are the
proteins predicted for DEHP using our P-PAN (dark purple are
the proteins with a high confidence score). Green edges are the
protein-protein interactions predicted from the String database
and purple edges are the protein-protein associations suggested by
P-PAN. In the String output network none of the GABA receptors
were found, which were identified as potential molecular targets
for DEHP using our P-PAN. Considering high confidence score
for both methods (String score.0.98), no overlaps between
predicted proteins were found. The interactions between predicted
proteins were removed for more clarity.
Found at: doi:10.1371/journal.pcbi.1000788.s003 (0.26 MB
DOC)
Figure S4 Distributions of the gene- disease scores from
GeneCards-AKS2 and OMIN. To integrate disease information
to the clusters, GeneCards was used as a source of disease-protein
connections. In order to limit the use of false positives present in
GeneCards, we mapped shared protein-disease association from
OMIN and GeneCards. According to the overlap curves, we set a
significant cut-off value of the GeneCards-AKS2 score (in red) of
60.
Found at: doi:10.1371/journal.pcbi.1000788.s004 (0.28 MB
DOC)
Text S1 Mining the P-PAN for chemicals associated with
diseases.
Found at: doi:10.1371/journal.pcbi.1000788.s005 (0.06 MB
DOC)
Text S2 Molecular targets predictions for chemicals.
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Found at: doi:10.1371/journal.pcbi.1000788.s006 (0.07 MB
DOC)
Table S1 Example of molecular target predictions for chemicals.
References: 1. Mahgoub AA, El-Medany AH (2001) Evaluation of
chronic exposure of the male rat reproductive system to the
insecticide methomyl. Pharmacol. Res. 44:73–80. 2. Bernard L,
Martinat N, Le´cureuil C, Cre´pieux P, Reiter E, Tilloy-Ellul A,
Chevalier S, Guillou F (2007) Dichlorodiphenyltrichloroethane
impairs follicle-stimulating hormone receptor-mediated signaling
in rat Sertoli cells. Reprod. Toxicol. 23:158–164. 3. Saqib TA,
Naqvi SN, Siddiqui PA, Azmi MA (2005) Detection of pesticide
residues in muscles liver and fat of 3 species of Labeo found in
Kalri and Haleji lakes. J. Environ. Biol. 26:433–438. 4. Flodstro¨m
S, Hemming H, Warngard L, Ahlborg UG (1990) Promotion of
altered hepatic foci development in rat liver cytochrome P450
enzyme induction and inhibition of cell-cell communication by
DDT and some structurally related organohalogen pesticides.
Carcinogenesis 11:1413–1417. 5. Sakai H, Iwata H, Kim EY,
Tsydenova O, Miyazaki N, Petrov EA, Batoev VB, Tanabe S
(2006) Constitutive androstane receptor (CAR) as a potential
sensing biomarker of persistent organic pollutants (POPs) in
aquatic mammal: molecular characterization expression level and
ligand profiling in Baikal seal (Pusa sibirica). Toxicol. Sci. 94:57–
70 6. Ding X, Staudinger JL (2005) Repression of PXR-mediated
induction of hepatic CYP3A gene expression by protein kinase C.
Biochem. Pharmacol. 69:867–873. 7. Matsuura I, Saitoh T, Tani
E, Wako Y, Iwata H, Toyota N, Ishizuka Y, Namiki M, Hoshino
N, Tsuchitani M, Ikeda Y (2005) Evaluation of a two-generation
reproduction toxicity study adding endpoints to detect endocrine
disrupting activity using lindane. J. Toxicol. Sci. Spec No 135–
161.
Found at: doi:10.1371/journal.pcbi.1000788.s007 (0.04 MB
DOC)
Table S2 Illustration of cpscore for approved drugs.
Found at: doi:10.1371/journal.pcbi.1000788.s008 (0.09 MB
DOC)
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